The FDA regulates pharmaceutical products across a spectrum that includes prescription drugs, over-the-counter medications, dietary supplements, compounded preparations, and research compounds. Products that fall within the FDA's regulatory scope are subject to manufacturing standards, labeling requirements, advertising restrictions, and distribution controls. Payment processors use the breadth and intensity of this regulatory framework as a basis for classifying pharmaceutical merchants as high-risk, because a compliance failure at the merchant level can generate regulatory consequences that reach the financial institutions processing the transactions.
Crypto payment processing does not exempt the pharmaceutical merchant from FDA compliance. The regulatory obligations attach to the product and the seller, not to the payment method. What pharmaceutical payment processing through 27 Blockchain does is separate the payment infrastructure from the regulatory risk assessment that traditional processors apply. The merchant remains fully responsible for compliance with all applicable FDA regulations. The merchant's ability to accept payments is no longer contingent on a processor's willingness to bear the indirect regulatory exposure.
